What changed today in Metabolic: 20 trial updates, 9 new studies
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
Semaglutide
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and marketed under brand names including Ozempic, Wegovy and Rybelsus for different indications.
High attention
- Editorial attention
- High attention
- Tracked this week
- 13
- Sources this week
- 5
- Last activity
- 4 hrs ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Semaglutide at a glance
- About this topic
- Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and marketed under brand names including Ozempic, Wegovy and Rybelsus for different indications.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: New trial registered: SWIFT (Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1…) (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Sep 30, 2026)
- Key facts from tracked records
- 20 clinical trials tracked from ClinicalTrials.gov
- 1 NPHLA briefing on this topic
What’s the latest on Semaglutide?
1 totalWhat do the official records show?
Primary sources and peer-reviewed research- New trial registered: SWIFT (Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1…) (opens the source in a new tab)
Phase 2, The Methodist Hospital Research Institute. Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endometrial Cancer; Fertility-Sparing Treatment (FST); Obesity & Overweight. I…
- Compounding stigma: An experimental study comparing perceptions of an individual using Ozempic, bariatric surgery, or behavior modification (opens the source in a new tab)
- New trial registered: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema (opens the source in a new tab)
Phase 3, Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by… (opens the source in a new tab)
Not applicable, Peking University People's Hospital. Conditions: Obesity; Chronic Kidney Disease; Albuminuria. Interventions: Finerenone; Finerenone Placebo; Semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets (opens the source in a new tab)
Novo Nordisk A/S. Conditions: Overweight; Obesity. Interventions: Semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity (opens the source in a new tab)
Phase 2, Zomagen Biosciences Ltd.. Conditions: Obesity. Interventions: Placebo; VTX3232 30 mg; Placebo in combination with semaglutide; VTX3232 30 mg in combination with semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or… (opens the source in a new tab)
Phase 3, Pfizer. Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Interventions: Semaglutide; Tirzepatide; Berobenatide. Investigational: trial-stage therapies are not approved for the use studied.
- New trial registered: A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight (opens the source in a new tab)
Phase 1, Novo Nordisk A/S. Conditions: Obesity; Overweight. Interventions: Semaglutide; Placebo semaglutide; Paracetamol. Investigational: trial-stage therapies are not approved for the use studied.
Which clinical trials are being tracked?
All trials- REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk A/S. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
Peking University People's Hospital. Conditions: Obesity; Chronic Kidney Disease; Albuminuria. Investigational — not approved for the use studied.
- A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk A/S. Conditions: Obesity. Investigational — not approved for the use studied.
- SCALA-TK-CM: A Retrospective Real-World Cohort Study
Novo Nordisk A/S. Conditions: Obesity; Type 2 Diabetes (T2D); Prediabetes; Cardiovascular Disease (CVD); Dyslipidemia; Metabolic Dysfunction-associ…. Investigational — not approved for the use studied.
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk A/S. Conditions: Obesity; Type 2 Diabetes. Investigational — not approved for the use studied.
Industry coverage
Headlines link to the original publication- FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s (opens the source in a new tab)
- #EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy (opens the source in a new tab)
- #EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes (opens the source in a new tab)
- Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds (opens the source in a new tab)